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INTRODUCTION
This paper contains a summary and the recommendations of a joint
European Society of Human Genetics (ESHG)/American Society of
Human Genetics (ASHG) position statement on responsible innovation
in prenatal screening with non-invasive prenatal testing (NIPT). This
statement was drafted by the Public and Professional Policy Committee
of the ESHG and the Social Issues Committee of the ASHG, and
endorsed by the boards of both societies in December 2014. The
statement is also endorsed by the Human Genetics Society of
Australasia, the Australasian Association of Clinical Geneticists, the
British Society for Genetic Medicine, the Czech Medical Genetics
Society, and the PHG Foundation (Cambridge, UK). The full
document with extensive references is published separately.1
SUMMARY OF THE ESHG/ASHG POSITION STATEMENT
This ESHG/ASHG position statement takes as its starting point the
internationally endorsed normative framework for prenatal screening,
stressing that the aim of the practice should be to facilitate informed
reproductive choices rather than preventing the birth of children with
speciﬁc abnormalities, and that the beneﬁts for those tested should
clearly outweigh any harms. Moreover, when screening is offered as a
public health programme, societal and justice aspects need to be taken
into account. This includes possible consequences for other
individuals and groups (including those living with the relevant
conditions), as well as cost-effectiveness of publicly funded services.
In the past few years, professional bodies and policy authorities have
recommended offering NIPT for common aneuploidies to women
who belong to a higher risk group, either based on maternal age or a
positive combined ﬁrst trimester screening test (cFTS). With recent
publications suggesting equally good test performance in lower-risk
populations, and depending on the health care setting, different
scenarios for NIPT-based screening for common autosomal aneuploidies
are possible, including NIPT as an alternative ﬁrst-tier test. The greater
accuracy and lower invasive follow-up testing rate that can thus be
achieved, has the potential of helping prenatal screening better achieve
its aim, provided that balanced pre-test information and non-directive
counseling are available as part of the screening offer. Concerns have
been raised that as a result of these same features (greater accuracy and
lower invasive follow-up testing rate), prenatal screening may increas-
ingly be regarded both by professionals and pregnant women as a
routine procedure that as such would not require much reﬂection.
This may have the consequence that women or couples are insufﬁ-
ciently prepared for the possible eventual diagnosis of a fetus with a
serious disorder. Avoiding such ‘routinisation’ effects may well be the
greatest ethical challenge of NIPT-based prenatal screening.
Depending on the use of targeted or non-targeted analysis and on
the level of resolution, NIPT for common autosomal aneuploidies may
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lead to ﬁndings of abnormalities in other chromosomes, including
submicroscopic abnormalities. This is not a new problem: such
ﬁndings also emerge at follow-up testing after positive cFTS. However,
at the NIPT stage, they precede decision making about invasive testing.
This may entail putting the pregnancy at risk for conﬁrming ﬁndings
that not only have a low positive predictive value (because of their low
frequency), but that, if conﬁrmed, may still have highly uncertain
implications for the expected phenotype. If enabling autonomous
decision making is the aim of prenatal screening, then as much as
reasonably possible, women or couples should be informed about the
possibility of additional ﬁndings and their possible implications. They
should also be given the opportunity to indicate whether or not they
would want to receive information about clinically relevant ﬁndings
beyond the scope of the screening offer.
A speciﬁc ethical issue related with NIPT is sex selection for non-
medical reasons. Depending on how the test is carried out, the
scenario with NIPT as a ﬁrst screening test might lead to information
about fetal sex being available at an early stage in all screened
pregnancies. Commercial companies offering NIPT currently also
provide this information on an optional basis. There is a concern that
some pregnant women and their partners may use this to have an
abortion if the sex of the fetus does not match their preference. The
best way to counteract improper use of information about fetal sex is
to avoid it becoming available as part of the test results.
It is expected that in the coming years, it will become possible to use
NIPT to screen for the same range of conditions that are currently tested
for using karyotyping or microarray technologies at the follow-up stage,
including sex-chromosomal and submicroscopic abnormalities. Com-
mercial providers have already begun expanding their tests to include
these conditions. However, this should not precede a careful assessment
of the beneﬁts and harms of doing so. Relevant aspects include: test
accuracy, counseling challenges, women’s preferences, the interests of the
future child (see below) and misuse of information about fetal sex.
Given the publication of proof of principle analysis of the entire fetal
genome from maternal plasma, it is expected to eventually become
technically possible to turn NIPT-based screening into a comprehen-
sive fetal genome scan, looking beyond chromosomal abnormalities to
Mendelian disorders and genetic risk proﬁles for multifactorial diseases.
Inevitably, this raises the question of what the scope of prenatal
screening for fetal abnormalities should be. Reasons for not expanding
prenatal screening beyond serious childhood disorders are the follow-
ing. Firstly, unlimited choice may paradoxically undermine rather than
serve or enhance reproductive autonomy. Secondly, given that
expanded prenatal screening will reveal later onset disorders as well
as abnormalities that might otherwise have remained undiagnosed, and
that these ﬁndings will not always lead to the woman asking for an
abortion, the interests and autonomy rights of the future child need to
be taken into account. Bringing a child into the world with all the
information from a full genome scan may lead to psychosocial harm
and amount to a violation of his or her ‘autonomy rights’.
Historically and ethically, prenatal screening for fetal abnormalities
such as Down syndrome should be distinguished from prenatal
screening for conditions relevant to a healthy outcome of the
pregnancy for the mother and child. New developments including
NIPT may increasingly lead to these types of prenatal screening
running together. What should be avoided here, is to confuse women
and couples with regard to what they are offered testing for, and what
they can accept or decline, and on what basis. A further expected
development is that more disorders will become treatable in utero. As a
consequence, prenatal screening for those disorders will open up more
options than only the choice between completion and termination of a
pregnancy, including treatments that may beneﬁt the health prospects
of the future child. As a result, new ethical questions may arise for
which the current ethical framework is inadequate. For instance: to
what extent do these new preventative options create obligations for
prospective parents?
In many countries, prenatal screening has in the past decades been
offered to pregnant women in the form of national or regional
population screening programmes. Whereas in the past, new screening
technologies have been readily introduced in these programmes, the
introduction of NIPT into clinical practice has until now been largely
left to commercial laboratories offering their version of the test
through individual practitioners and practices. Governments and
public health authorities seem hesitant to be involved in this process.
Given the importance of offering NIPT in a setting in which all
relevant aspects (including information and counseling) are quality
controlled, it is time that these actors take a more active role.
The notion that prenatal screening should be regarded a public
health responsibility does not necessarily entail that all costs are paid
from public money without any (co-)payment from those being
tested. It is important to note that these are separate (though
connected) issues. In light of the aim of providing options for
reproductive choice, it might be argued that asking women to pay
for prenatal screening increases the awareness that there is truly
a choice to be made. On the other hand, depending on the height of
the ﬁnancial barrier, this may limit access to prenatal screening to
those who are better off, which raises an issue of justice.
Finally, NIPT makes it possible in theory to offer prenatal testing for
fetal abnormalities as a direct-to-consumer test. However, in order to
maintain minimum quality standards, prenatal testing for fetal
abnormalities should always be offered through health professionals
with the expertise and training to provide the necessary pre-and post-
test information and counseling.
RECOMMENDATIONS
1. NIPT offers improved accuracy when testing for common
autosomal aneuploidies compared with existing tests such as
cFTS. However, a positive NIPT result should not be regarded as a
ﬁnal diagnosis: false positives occur for a variety of reasons
(including that the DNA sequenced is maternal and fetal in origin
and that the fetal fraction derives from the placenta as well as the
developing fetus). Thus women should be advised to have a
positive result conﬁrmed through diagnostic testing, preferably by
amniocentesis, if they are considering a possible termination of
pregnancy.
2. The better performance including lower invasive testing rate of
NIPT-based screening should not lead to lowering standards for
pre-test information and counseling. This is especially important in
the light of the aim of providing pregnant women with meaningful
options for reproductive choice. There should be speciﬁc attention
paid to the information needs of women from other linguistic and
cultural backgrounds or who are less health literate.
3. If NIPT is offered for a speciﬁc set of conditions (eg trisomies 21,
18 and 13), it may not be reasonably possible to avoid additional
ﬁndings, such as other chromosomal anomalies or large scale
insertions or deletions. As part of pre-test information, women
and couples should be made aware of the possibility of such
additional ﬁndings and the range of their implications. There
should be a clear policy for dealing with such ﬁndings, as much as
possible also taking account of pregnant women’s wishes with
regard to receiving or not receiving speciﬁc information.
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4. Expanding NIPT-based prenatal screening to also report on sex-
chromosomal abnormalities and microdeletions not only raises
ethical concerns related to information and counseling challenges
but also risks reversing the important reduction in invasive testing
achieved with implementation of NIPT for aneuploidy, and is
therefore currently not recommended.
5. Emerging opportunities for combining prenatal screening for fetal
abnormalities with screening aimed at prevention may undermine
adequate counseling by sending mixed messages. The objective of
any prenatal screening activity should be made explicit and, as far
as possible, forms of prenatal screening with different aims should
be presented separately. If not physically possible, this separation
should at least be made conceptually when providing the relevant
information.
6. In countries where prenatal screening for fetal abnormalities is
offered as a public health programme, governments and public
health authorities should adopt an active role to ensure the
responsible introduction of NIPT as a second or ﬁrst-tier screen-
ing test for Down syndrome and other common autosomal
aneuploidies. This entails ensuring quality control also extending
to the non-laboratory aspects of NIPT-based prenatal screening
(information and counseling), education of professionals, sys-
tematic evaluation of all aspects of the screening programme as
well as promoting equity of access for all pregnant women within
the conﬁnes of the available budget, and setting up a governance
structure for responsible further innovation in prenatal screening.
7. Different scenarios for NIPT-based screening for common
autosomal aneuploidies are possible, including NIPT as an
alternative ﬁrst-tier option. The inevitable trade-offs underlying
those scenarios should not just be regarded as a matter of
screening technology and health economics; the question is also
how these trade-offs enable or impede meaningful reproductive
choices and how they affect both the balance of beneﬁts and
burdens for pregnant women and their partners, and the screen-
ing goals and values acceptable to society.
8. In order to adequately evaluate prenatal screening practices, there
is a need to further develop and validate measures of informed
choice as well as interventions aimed at enabling informed
choices. The transition to NIPT-based prenatal screening presents
an opportunity to ﬁll this gap in knowledge.
9. In the light of sequencing technologies becoming better and
cheaper, there is an acute need for a proactive professional and
societal debate about what the future scope of prenatal screening
for fetal abnormalities should be. As argued in this document,
there are strong ethical reasons for not expanding the scope of
prenatal screening beyond serious congenital and childhood
disorders.
10. The scenario in which prenatal screening would open up
possibilities for fetal therapy in addition to autonomous
reproductive choice raises fundamental questions about the
relation between reproductive autonomy and parental respon-
sibility that require an in depth proactive ethical analysis.
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